MCK
McKesson goes shopping
McKesson apparently looked at the calendar, looked at its balance sheet, and said: sure, let’s do a $5.8 billion deal. The company is teaming up with Clayton, Dubilier & Rice to buy Option Care Health, one of the biggest providers of home and infusion services in the U.S.
That’s not exactly a tiny tuck-in acquisition. It’s a reminder that McKesson isn’t just a sleepy middleman moving boxes around. It’s still very much in deal-making mode, and this one adds another layer to its healthcare distribution and services empire.
Why investors should care
A deal this size matters for a few reasons:
- It signals McKesson still has appetite for big strategic M&A, not just buybacks and quarterly housekeeping.
- Option Care gives the buyers more exposure to specialty and home-based care, which is basically where a lot of healthcare is slowly drifting anyway.
- The market will be watching for execution risk, because $5.8 billion buys you growth hopes, integration headaches, and a few sleepless nights.
Big picture
For McKesson holders, this is the classic “grow by acquisition” playbook in a very expensive outfit. If it works, the company looks smarter and bigger. If it stumbles, you get the usual M&A hangover. Either way, this is the kind of move Wall Street likes to poke at with a very sharp stick.